Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Marinus Pharmaceuticals Inc. | Ganaxolone - (RESET) | Established status epilepticus (SE) | Phase 2 | Trial Discontinued | Oral | Neurology |
| Marinus Pharmaceuticals Inc. | Ganaxolone - (Violet) | PCDH19-related epilepsy | Phase 2 | Trial Completed | Oral | Genetic Disorder |
| Marinus Pharmaceuticals Inc. | Ganaxolone | Fragile X Syndrome | Phase 2 | Trial Discontinued | Oral Intravenous | Genetic Disorder |
| Marinus Pharmaceuticals Inc. | Ganaxolone - (Magnolia) | Postpartum depression | Phase 2 | Trial Discontinued | Oral | Psychiatric |
| Marker Therapeutics Inc. | MT-401-OTS - (ARTEMIS) | Acute Myeloid Leukemia (AML) | Phase 2 | Trial Planned | Intravenous | Oncology |
| Marker Therapeutics Inc. | TPIV200 | Triple-negative breast cancer (TNBC) | Phase 2 | Trial Discontinued | Intramuscular | Oncology |
| Marker Therapeutics Inc. | TPIV200 | Platinum-sensitive ovarian cancer | Phase 2 | Trial Discontinued | Intramuscular | Oncology |
| Matinas Biopharma Holdings Inc. | Oral amphotericin b (MAT2203) - (EnACT) | Cryptococcal meningitis | Phase 3 | Withdrawn | Oral | Anti-Fungal |
